Side-by-side financials for FDMT and ARGX. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | FDMT | ARGX |
|---|---|---|
| Market cap | - | $55.63 B |
| US-listed rank | - | #303 |
| Revenue (latest FY) | $85.21M | - |
| Net income (latest FY) | -$140.11M | - |
| Net margin | -164.4% | - |
| SEC filings | 397 | 272 |
Full pages: 4D Molecular Therapeutics, Inc. and ARGENX SE, or browse the full rankings.